Thermo Fisher highlights AI research tools at BIO International, shares steady on NYSE

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 10:33.

Thermo Fisher Scientific (US8835561023) uses the BIO International Convention in San Diego this week to showcase expanded capabilities in manufacturing, clinical development and AI-enabled research solutions, according to a June 23 report from BioSpace and event communications at the NASDAQ-listed group.BioSpace report on Thermo Fisher at BIO International 2026 The presentation underscores the company’s role as a major life-science tools supplier alongside sector peers Danaher and Agilent Technologies.

What Thermo Fisher presents at BIO

At BIO International 2026, Thermo Fisher is highlighting integrated offerings that span biopharmaceutical manufacturing services, clinical trial support and AI-enhanced discovery platforms, according to the BioSpace article dated June 23, 2026.BioSpace report on Thermo Fisher at BIO International 2026 The company emphasizes how data analytics and artificial intelligence can streamline R&D and scale-up for biopharma clients.

The tools presented include platforms for process development, clinical trial logistics and digital solutions that connect laboratory instruments with cloud-based analytics, positioning Thermo Fisher as a partner across the drug lifecycle from preclinical research to commercial supply for customers listed on exchanges such as NYSE and NASDAQ.BCC Research profile of Thermo Fisher Scientific

Operations, scale and sector peers

Thermo Fisher generated around 44.6 billion US dollars in revenue in 2025 and employed roughly 125,000 people worldwide, according to a recent company profile by BCC Research.BCC Research profile of Thermo Fisher Scientific The group focuses on laboratory products, analytical instruments and biopharma services for research, diagnostics and manufacturing.

In the life-science tools space, Thermo Fisher competes with Danaher and Agilent, both also listed in major US indices such as the S&P 500 and trading on NYSE or NASDAQ, where investors compare margins and growth in analytical instruments and contract manufacturing services.Reuters company overview for Thermo Fisher

What the company sells

Thermo Fisher earns most of its revenue with laboratory products, analytical instruments and biopharma services, spanning consumables, reagents, DNA sequencing systems, mass spectrometers and contract development and manufacturing services for biopharmaceutical firms worldwide.BCC Research profile of Thermo Fisher Scientific

Where the stock trades today

The Thermo Fisher shares (US8835561023) trade on the NYSE under the ticker TMO and most recently changed hands at around 464 US dollars on June 23, 2026, according to Tallac options price data for the US listing.Tallac options quote for TMO

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on sources deemed reliable but cannot be guaranteed.